Back to Results
First PageMeta Content
Organofluorides / Prostate / Eastern Cooperative Oncology Group / Antiandrogen / Adjuvant therapy / Nilutamide / Management of prostate cancer / Mark Soloway / Medicine / Andrology / Prostate cancer


Early versus deferred androgen suppression in the treatment of advanced prostatic cancer
Add to Reading List

Document Date: 2013-02-22 08:30:46


Open Document

File Size: 355,33 KB

Share Result on Facebook

City

Minneapolis / Little Rock / /

Company

Agency for Healthcare Research Quality Early / Veterans Administration Cooperative Urological Research Group / John Wiley & Sons Ltd. / Eastern Cooperative Oncology Group / Research Council Prostate Cancer Working Party Investigators Group / MEDLINE / Agency for Healthcare Research / Urologic Cancers Group / Prostate Cancer Trialist Collaborative Group / /

Country

United States / /

Currency

USD / /

/

Event

FDA Phase / /

Facility

The Cochrane Library / Cochrane Library / Blue Shield Association Technology Evaluation Center / Blue Shield Association Technology Evaluation Center/Evidence-based Practice Center / /

IndustryTerm

treatment / treatment for men with advanced prostate cancer / search process / deferred / treatment of prostate cancer / early treatment / deferred therapy / search strategy / immediate treatment / early therapy / therapies for advanced prostate cancer / online databases / Search methods / deferred treatment / treatment of advanced prostate cancer / immediate and deferred treatment / treatment of advanced prostatic cancer / electronic search / literature search / treatment for advanced prostate cancer / /

MedicalCondition

disease progression / locally advanced disease / M1 disease / disseminated metastasis / asymptomatic distant metastases / defined disease / developed symptomatic metastases / asymptomatic metastatic prostate cancer / extensive metastatic disease / extra-skeletal metastases / local disease / asymptomatic metastases / metastatic disease / prostatic neoplasms / minimally advanced disease / clinically localized disease / previously untreated carcinoma / VA Cochrane Prostate Disease / prostate cancer / Cochrane Prostatic Diseases / gynecomastia / BACKGROUND Prostate cancer / lymph node metastases / tumor / earlier disease / advanced prostate cancer / cancer / disease / IV disease / nodal metastases / advanced prostatic cancer / T2 disease / IV prostate cancer / localized disease / disseminated disease / demonstrated metastases / M0 disease / Urologic Cancer / earlier / lower volume disease / metastases / distant metastases / /

MedicalTreatment

radiation therapy / hormone therapy / hormone treatment / surgery / Hormone therapies / radiation / radiation treatment / hormonal therapy / prostatectomy / adjuvant therapy / /

Organization

Department of Internal Medicine / Blue Cross and Blue Shield Association Technology Evaluation Center / ACKNOWLEDGEMENTS Blue Cross Blue Shield Evidence-based Practice Center / Blue Cross and Blue Shield Association Technology Evaluation Center/Evidence-based Practice Center / United States Medicare / Agency for Healthcare Research and Quality / /

Person

Timothy J Wilt / /

Position

physician / gov. Editorial group / participating physician / General / /

Product

flutamide / bicalutamide / Diethylstilbestrol / to / DES / /

ProvinceOrState

Minnesota / Oregon / Arkansas / /

Technology

radiation / X-ray / analysis The protocol / /

URL

http /

SocialTag